Form 4: Kura Oncology Director Helen Collins Granted Significant Stock Options

Kura Oncology Director Helen Collins was granted 28,500 stock options with an exercise price of $6.57, aligning her interests with long-term shareholder value.

Summary

• Helen Louise Collins, a Director of Kura Oncology, Inc. (KURA), reported the acquisition of derivative securities.
• The transaction involved an option to purchase 28,500 shares of common stock.
• The exercise price for these options is $6.57 per share.
• The options were granted on June 5, 2025.
• These options will vest in full on the one-year anniversary of the grant date, which is June 5, 2026.
• The expiration date for these options is June 4, 2035.
• Following this transaction, Helen Collins beneficially owns 28,500 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of aligning management's interests with shareholder value, representing a standard and expected form of equity compensation. It does not indicate any negative operational or financial issues.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company's stock, potentially motivating decisions that enhance shareholder value.
• Equity compensation is a standard practice for attracting and retaining experienced board members.

Risks

• The value of the granted options is contingent on the future performance of Kura Oncology's stock price; if the stock price does not exceed the exercise price, the options may expire worthless.
• Dilution risk for existing shareholders if a significant number of options are exercised in the future, although this specific grant is relatively small in the context of a public company.

Future Outlook

The grant of stock options with a 10-year expiration period and a one-year vesting schedule indicates a long-term incentive for the director, suggesting a focus on sustained company performance.

Industry Context

The granting of stock options to directors is a common and widely accepted practice within the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to align leadership incentives with shareholder returns.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation across the biotech and broader corporate landscape, comparable to practices at companies like Amgen, Gilead Sciences, or Biogen, which frequently use stock-based incentives for their board members.
• The vesting schedule (one-year cliff) and the 10-year term are typical for director option grants, reflecting a balance between immediate incentive and long-term commitment, similar to compensation structures seen in many publicly traded life sciences companies.

Related Party Transactions

• The grant of stock options to Helen Louise Collins, a Director of Kura Oncology, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value, potentially leading to decisions that benefit the stock price.
• Employees: No direct impact mentioned, but it reinforces the company's compensation philosophy for leadership.

Next Steps

• The options will vest in full on June 5, 2026, at which point Helen Collins will be able to exercise them.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, stock options, insider transaction, director compensation, equity compensation, beneficial ownership, biotechnology, pharmaceuticals